Iron Metabolism Disorders Market Predicted to Grow at a CAGR of 3.65% during 2025-2035, Impelled by Growing Burden of Chronic Diseases

Iron Metabolism Disorders Market Outlook 2025-2035:

The 7 major iron metabolism disorders market are expected to exhibit a CAGR of 3.65% during 2025-2035. Emerging cases of anemia, hemochromatosis, and conditions related to iron deficiency are driving the growth of the disorder market for iron metabolism. Advancements in diagnostic tools, awareness, and better therapeutic options will also fuel this expansion. An aging population and progressively increased prevalence of chronic diseases, including kidney and liver disorders, are additional reasons for demand increase. Pharmaceutical and biotech companies are discovering new therapies that will help improve the condition of imbalances caused due to iron deficiency. Improved healthcare facilities and government support are further fueling the market growth.

Growing Burden of Chronic Diseases: Driving the Iron Metabolism Disorders Market

The most significant reason for the growth of the iron metabolism disorders market is the increasing incidence of chronic diseases. CKD, cancer, liver diseases, and inflammatory disorders disrupt normal iron balance and consequently cause complications like ACD and iron overload syndromes. In CKD patients, the body's capacity to produce erythropoietin decreases, and iron absorption is also hindered leading to the need for treatment with iron supplements or erythropoiesis-stimulating agents. Thus, impairment of iron metabolism also necessitates therapy in certain liver conditions like cirrhosis and hemochromatosis. In fact, cancer-anemia itself is a feature wherein treatment modalities, including chemotherapy and tumor growth, can cause iron imbalance thereby requiring a need for iron-modifying therapy. Thus, another trigger for treatment demand is gastrointestinal disorders reducing iron absorption, which include inflammatory bowel diseases (IBD). Growing awareness of these disorders and better diagnostics are leading to earlier diagnosis with therapy starting much sooner than before. Increasingly, healthcare providers tailor patient treatment modalities to their individual needs-specific intravenous iron therapy, oral iron supplements, or iron chelation therapies, depending on the nature of the overload. Another factor driving the market is the aging population, which is more susceptible to chronic conditions and related iron problems. Advances in treatments, including hepcidin modulators and ferroportin inhibitors, are also transforming the therapeutic scenario. Government support for research into iron metabolism disorders is also helping to drive the development of the market. There has also been increased healthcare expenditure and greater accessibility to advanced treatments across the globe, with major emphasis to emerging markets. This has created the demand for solutions in iron metabolism disorders.

Development of Novel Therapies and Pharmacological Treatments: Contributing to Market Expansion

One of the major factors driving the market in this sector is the discovery of new therapies and pharmacological treatments for disorders in iron metabolism. The increased prevalence of diseases such as iron deficiency anemia, hereditary hemochromatosis, and anemia of chronic disease necessitates better treatments. More targeted and individualized treatments have been developed with the advent of iron chelators, hepcidin mimetics, and gene therapies. These innovations provide improved treatment outcome as well as facilitate market expansion due to these products being safe and efficient. Secondly, heightened awareness of how disturbances in the iron metabolism correlate with chronic disease increases the necessity of new therapeutics. Advanced studies and partnering pharmaceutical companies and biotech businesses with academic bodies further speed the research process and lead to fast results. As regulatory bodies sanction these new therapies, the market for iron metabolism disorders will see a huge prospective growth. This rising interest and investment around iron metabolism further highlight its importance within the pharmaceutical industry.

Marketed Therapies in Iron Metabolism Disorders Market

Exjade (Deferasirox): Novartis

Exjade (Deferasirox), developed by Novartis, is an oral iron chelator used to treat chronic iron overload caused by blood transfusions, such as in thalassemia. It works by binding to excess iron in the body and promoting its excretion, helping to prevent iron-related organ damage. Exjade provides an effective option for managing iron metabolism disorders and reducing the risk of complications from iron overload.

Ferriprox (Deferiprone): Apotex

Ferriprox (Deferiprone), developed by Apotex, is an oral iron chelator used for the treatment of iron overload disorders, such as thalassemia and other conditions requiring long-term blood transfusions. It works by binding to excess iron in the body and facilitating its removal, helping to reduce iron toxicity and prevent organ damage. Ferriprox offers an effective treatment option for managing iron metabolism imbalances in patients with chronic iron overload.

Emerging Therapies in Iron Metabolism Disorders Market

PTG-300 (Rusfertide): Protagonist Therapeutics

PTG-300 (Rusfertide) is a novel investigational treatment developed by Protagonist Therapeutics for addressing iron overload conditions, including hereditary hemochromatosis. It works by mimicking the natural hormone hepcidin, which helps control the body’s iron levels. By reducing the absorption of iron and promoting its redistribution, PTG-300 offers a more precise approach to managing iron imbalance, potentially reducing reliance on conventional treatments like phlebotomy and iron chelation therapy. This therapy presents a promising alternative for patients with disorders related to iron metabolism.

Detailed list of emerging therapies in Iron Metabolism Disorders is provided in the final report.

Leading Companies in the Iron Metabolism Disorders Market:

The market research report by IMARC encompasses a comprehensive analysis of the competitive landscape in the market. Across the global iron metabolism disorders market, several leading companies are at the forefront of developing integrated platforms to enhance the management of iron metabolism disorders. Some of the major players include Novartis, and others. These companies are driving innovation in the iron metabolism disorders market through continuous research, diagnostic tools, and expanding their product offerings to meet the growing demand for iron metabolism disorders.

Key Players in Iron Metabolism Disorders Market:

The key players in the iron metabolism disorders market who are in different phases of developing different therapies are Apotex, Protagonist Therapeutics, Novartis, and others.

Regional Analysis:

The major markets for iron metabolism disorders include the United States, Germany, France, the United Kingdom, Italy, Spain, and Japan. According to projections by IMARC, the United States has the largest patient pool for iron metabolism disorders while also representing the biggest market for its treatment. Recent advancements in the iron metabolism disorder market have significantly enhanced treatment options and patient outcomes. New oral iron formulations with improved absorption and fewer gastrointestinal side effects are increasing patient adherence to therapy. Intravenous iron treatments have also become more widely used, allowing for quicker replenishment of iron levels and fewer complications, especially for those with severe anemia or absorption issues. Additionally, combination therapies that pair iron with vitamin C or other absorption enhancers are being explored to improve effectiveness. Public health initiatives are also raising awareness of iron deficiency anemia, resulting in earlier diagnosis and better management of the condition.

Recent Developments in Iron Metabolism Disorders Market:

• In September 2024, an endocrinology study evaluated the effect of liraglutide, a drug used to treat diabetes, on iron metabolism in a mouse model of hereditary hemochromatosis, diet-induced obesity, and glucose intolerance. This study demonstrated that liraglutide can potentially regulate the levels of iron and improve glucose tolerance, further adding to the understanding of the drug's potential metabolic benefits. These findings contribute to the growing body of evidence that liraglutide may have a place in the management of iron overload conditions, often associated with metabolic disorders, aside from its established use in diabetes. The study lays the foundation for further research into its potential therapeutic applications in humans.

Key information covered in the report

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

 Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the iron metabolism disorders market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the iron metabolism disorders market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report offers a comprehensive analysis of current iron metabolism disorders marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

 Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. Across the six major continents and 100+ countries, we work alongside our business partners as one team with a common ambition to achieve unparallelled results, gain a competitive edge, and transform industries. IMARC Group excels in understanding its clients’ business priorities and delivering tailored solutions that drive meaningful outcomes. Our client base spans over 3,000 organizations in the private, public, and social sectors, ranging from high-growth startups to Fortune 500 companies.

Contact US

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Phone Number: - +1 631 791 1145, +91-120-433-0800